Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Completes Acquisition of USB

NEW YORK (GenomeWeb News) – Affymetrix today said that it has completed its previously announced acquisition of USB Corp. for approximately $75 million in cash.
USB, a privately held firm based in Cleveland, Ohio, sells three product lines: molecular biology enzymes and kits, biochemical reagents, and membrane protein research tools.
Its roots date back to the 1970s when it was known as United States Biochemical. After Amersham Life Science purchased United States Biochemical in 1993 and then merged with Pharmacia Biotech in 1997, USB’s management team bought the company’s three main product lines back from Amersham Pharmacia Biotech to create USB in 1998.
Affymetrix President Kevin King said in a statement today that the acquisition “immediately expands our talent base, enhances our whole-product solution offering, and creates new, long-term growth opportunities.”
Earlier this month, Stephen Fodor, Affy's chairman and CEO, told attendees of the JPMorgan Healthcare Conference in San Francisco that it plans to use USB's reagents for a new technology it is developing that combines DNA sequencing and microarrays.
At the time, Fodor said the new technology was "one of the reasons why we acquired USB."
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.